loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Dimethyltryptamine

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Dimethyltryptamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    atai Life Sciences Announces First Subject Dosed in Phase 1 Trial
    atai Life Sciences Announces First Subject Dosed in Phase 1 Trial

    05 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/05/2528522/0/en/atai-Life-Sciences-Announces-First-Subject-Dosed-in-Phase-1-Trial-of-Buccal-and-IV-VLS-01-a-Synthetic-Form-of-DMT.html

    GLOBENEWSWIRE
    05 Oct 2022
    Share Share
    Core One Labs' Scientists Successfully Complete Breakthrough in Producing API
    Core One Labs' Scientists Successfully Complete Breakthrough in Producing API

    02 Sep 2022

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=714615

    ACCESSWIRE
    02 Sep 2022
    Share Share
    Cybin completes purchase of anxiety disorder treatment study
    Cybin completes purchase of anxiety disorder treatment study

    12 Jul 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/cybin-anxiety-disorder-treatment-study/

    CLINICALTRIALSARENA
    12 Jul 2022
    Share Share
    Small Pharma Reports Fiscal Third Quarter 2021 Highlights
    Small Pharma Reports Fiscal Third Quarter 2021 Highlights

    31 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/31/2376167/0/en/Small-Pharma-Reports-Fiscal-Third-Quarter-2021-Highlights.html

    GLOBENEWSWIRE
    31 Jan 2022
    Share Share
    Algernon Discloses Novel Salt Patent Strategy as Part of Psychedelic Drug DMT IP
    Algernon Discloses Novel Salt Patent Strategy as Part of Psychedelic Drug DMT IP

    24 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/24/2371542/0/en/Algernon-Pharmaceuticals-Discloses-Novel-Salt-Patent-Strategy-as-Part-of-its-Psychedelic-Drug-DMT-Intellectual-Property.html

    GLOBENEWSWIRE
    24 Jan 2022
    Share Share
    Algernon Files for Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
    Algernon Files for Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

    19 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/19/2369181/0/en/Algernon-Pharmaceuticals-Files-for-Clinical-Trial-and-Ethics-Approval-for-Phase-1-DMT-Human-Stroke-Study.html

    GLOBENEWSWIRE
    19 Jan 2022
    Share Share